Literature DB >> 8138947

Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine A1 receptor.

S Ali1, S J Mustafa, W J Metzger.   

Abstract

Recently, there has been an increasing interest in adenosine as a potential mediator of allergic asthma. In the present study, we used the allergic rabbit model developed in our laboratory to study the airway responses to adenosine and receptor binding in allergic lung vs. normal. Neonatal, pathogen-free rabbit litter mates were injected intraperitoneally within 24 hr of birth with ragweed pollen extract (1 mg/ml) to produce preferentially allergen-specific immunoglobulin E. Immunization produced bronchial airway hyperresponsiveness. Aerosolized adenosine (0.156-10 mg/ml) caused a dose-dependent bronchoconstriction (PC50 adenosine = 1.64 +/- 0.84 mg/ml). 9-Chloro-2-(2-furyl)[1,2,4]triazole[1,5- c]quinazolin-5-amine (CGS-15943), a nonxanthine adenosine receptor antagonist, significantly inhibited the adenosine-induced airway obstruction in term of dynamic compliance (P < .05). Adenosine also increased the lung resistance in a dose-dependent manner which was significantly inhibited by CGS-15943 (P < .05). Nonimmunized, pathogen-free, age-matched rabbits (control) did not respond to adenosine at these same concentrations. Adenosine also produced a concentration-dependent (10(-9)-10(-4) M) contraction of isolated tracheal and bronchial airway rings in vitro from allergic rabbits but had no detectable effect on normal rabbit airway smooth muscle. Peripheral airway smooth muscles (secondary and tertiary) were more responsive to adenosine than central (tracheal) airways. The contraction produced by 10(-4) M adenosine in primary, secondary and tertiary airways was 90, 135 and 265% of the contraction produced by 50 mM KCl, respectively. CGS-15943 (10(-7) M) significantly inhibited the adenosine-induced contraction (P < .05) shifting the dose-response curve to the right.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8138947

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

Review 1.  Recent advances in molecular biological techniques and their relevance to pulmonary research.

Authors:  B W Robinson; D J Erle; D A Jones; S Shapiro; W J Metzger; S M Albelda; W C Parks; A Boylan
Journal:  Thorax       Date:  2000-04       Impact factor: 9.139

2.  Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits.

Authors:  A el-Hashim; B D'Agostino; M G Matera; C Page
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 3.  Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma.

Authors:  Raymond B Penn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-16       Impact factor: 3.000

Review 4.  Adenosine signaling and the regulation of chronic lung disease.

Authors:  Yang Zhou; Daniel J Schneider; Michael R Blackburn
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

5.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 6.  Adenosine receptors and asthma.

Authors:  Constance N Wilson; Ahmed Nadeem; Domenico Spina; Rachel Brown; Clive P Page; S Jamal Mustafa
Journal:  Handb Exp Pharmacol       Date:  2009

7.  Tissue distribution of adenosine receptor mRNAs in the rat.

Authors:  A K Dixon; A K Gubitz; D J Sirinathsinghji; P J Richardson; T C Freeman
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

8.  Contractile responses to adenosine, R-PIA and ovalbumen in passively sensitized guinea-pig isolated airways.

Authors:  Timothy J Martin; Kenneth J Broadley
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

9.  Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Authors:  Yang Zhou; Jayasimha N Murthy; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

10.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.